Recombinant influenza viruses with stabilized HA for replication in eggs
AssigneesWisconsin Alumni Research Foundation (WARF), The University of Tokyo
InventorsYoshihiro Kawaoka, Shinya Yamada, Shiho Chiba
Life of this patent
Estimating the term…
Abstract
Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified. neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation.
Claims20
An isolated recombinant influenza virus comprising a selected NA viral segment encoding at least two selected residues in NA, wherein the residues are selected from residue S, T, I, L, A, N, W, Y, P, V, or G at position 245 and residue S, T, P, Y, W, A, N, I, L, or V at position 346, wherein the numbering is relative to SEQ ID NO:3, wherein the recombinant influenza virus has enhanced replication in avian eggs or has a reduction in HA mutations when grown in avian eggs relative to a corresponding influenza virus that has a NA that encodes an asparagine at residue 245, or encodes a glycine at residue 346, or any combination thereof.
A method to prepare influenza virus, comprising:
- contacting a cell with:
- a vector for vRNA production comprising a promoter operably linked to an influenza virus PA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus PB1 DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus PB2 DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus HA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus NP DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus NA DNA linked to a transcription termination sequence, a vector for vRNA production comprising a promoter operably linked to an influenza virus M DNA linked to a transcription termination sequence, and a vector for vRNA production comprising a promoter operably linked to an influenza virus NS DNA linked to a transcription termination sequence, wherein the PB1, PB2, PA, NP, NS, and M DNAs in the vectors for vRNA production are from one or more influenza vaccine virus isolates, wherein the NA DNA in the vector for vRNA production encodes a NA having a residue selected from S, T, I, L, A, N, W, Y, P, V, or G at position 245 and residue S, T, P, Y, W, A, N, I, L, or V at position 346, wherein the numbering for NA residues is relative to SEQ ID NO:3;
- and
- a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PB1, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus PB2, and a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NP, and optionally a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus HA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NA, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus M1, a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus M2, or a vector for mRNA production comprising a promoter operably linked to a DNA segment encoding influenza virus NS2;
- in an amount effective to yield infectious influenza virus.
Dependencies are inferred from the claim text.